Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to ...
Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology ...
Teva Pharmaceutical Industries Limited TEVA recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone). The regulatory body has now approved Uzedy (50 mg, 75 ...
The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 ...
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI (Long-Acting ...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, October 10, 2025--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles.
The Boston City Council struck down a resolution opposing safe injection sites, with proponents rejecting notions that legalizing such centers would incentivize addicts to shoot up and saying that ...
Scientists in China have developed a revolutionary new “bone glue” that can heal fractures, which could traditionally take months to heal, in a matter of minutes, according to a report. Product ...
Pfizer is facing a landmark lawsuit in the US brought on behalf of more than 1,000 women who say they developed brain tumors after taking the popular contraceptive injection Depo-Provera. On Monday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback